Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study

Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study

Yu-Hung Fang,1 Yao-Hsu Yang,2–5 Meng-Jer Hsieh,6,7 Ming-Szu Hung,8,9 Yu-Ching Lin1,8 1Division of Thoracic Oncology, Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi Branch, Puzi City, Chiayi County, Taiwan, R.O.C; 2Department of Traditional Chinese...

Full description

Bibliographic Details
Main Authors: Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC
Format: Article
Language:English
Published: Dove Medical Press 2019-09-01
Series:Cancer Management and Research
Subjects:
proton pump inhibitor
epidermal growth factor receptor
non-small cell lung cancer
gefitinib
tyrosine kinase inhibitor
National Health Insurance Research Database.
Online Access:https://www.dovepress.com/concurrent-proton-pump-inhibitors-increase-risk-of-death-for-lung-canc-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/concurrent-proton-pump-inhibitors-increase-risk-of-death-for-lung-canc-peer-reviewed-article-CMAR

Similar Items